Multidisciplinary Management of Locoregional Non–Small Cell Lung Cancer

Multidisciplinary Management of Locoregional Non–Small Cell Lung Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Mediastinal Staging in Non–Small Cell Lung Cancer

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 2: PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 3: Durvalumab in Stage III NSCLC Based on Performance Status

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 4: Treating for Stage III NSCLC After Progression on Durvalumab

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 5: Varied Timing of IO Therapy in Patients With Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 6: ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 7: Molecular testing in Patients With Metastatic NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 8: Integrating Perioperative Immunotherapy Strategies in NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 9: Multidisciplinary Management of Patients With Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Trending on OncLive

Adjuvant Osimertinib Keeps OS Benefit at 8 Years in Resected EGFR-Mutated Stage IB to IIIA NSCLC

PAPILLON: Frontline Amivantamab Plus Chemotherapy Yields 34.3-Month Median OS in EGFR Exon 20 Insertion–Positive NSCLC

Zidesamtinib Yields High Response Rates in TKI-Naive Advanced ROS1+ NSCLC

DESTINY-Lung04 Showcases PFS Benefit With First-Line T-DXd in HER2-Mutant NSCLC

FDA Approves Aminolevulinic Acid Hydrochloride Plus PDT for Basal Cell Carcinoma